CircuLite® to Present at Lazard Capital Markets Healthcare Conference

SADDLE BROOK, N.J.--()--CircuLite®, Inc. will be presenting at the Lazard Capital Markets Healthcare Conference, being held November 15-16, 2011 in New York City. Daniel Burkhoff, M.D., Ph.D., Chief Medical Officer, will deliver a corporate presentation on November 16, 2011 at 9:00 AM EST in Grand Ballroom Annex B. CircuLite is developing the Synergy® Pocket Micro-pump, the first micro-pump designed to provide long-term, partial circulatory support to improve the quality of life for a broad range of chronic heart failure patients.

About Synergy®

The Synergy® Pocket Micro-pump represents a new approach to minimally invasive circulatory support that can transform chronic heart failure management by providing a less-invasive, elective treatment option for patients before their disease state becomes emergent. Synergy is the first implantable system designed to provide partial circulatory support for long-term use in millions of unserved patients that have NYHA Class IIIb/early IV disease.

CircuLite’s patented micro-pump provides up to 4.25 L/min of flow, which increases total cardiac output, offloads the heart, allowing it to rest, and potentially enables beneficial recovery of heart function. The size of a AA battery, the device is small enough to be implanted subcutaneously in a “pacemaker-like” pocket through a minimally-invasive procedure.

About CircuLite®

CircuLite is transforming heart failure treatment with the development of minimally-invasive circulatory support devices designed to provide long-term support. By enabling a proactive and lower-risk treatment approach by supplementing a patient’s native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite’s pipeline of devices is lead by the Synergy® Pocket Micro-pump, the world’s smallest implantable blood pump currently in a CE Mark clinical trial. Next-generation Synergy micro-pumps include an endovascular system, a fully-implantable system and a pediatric system. For more information on CircuLite and the Synergy Pocket Micro-pump devices, visit our website at www.CircuLite.net.

CAUTION: Investigational Device. Limited by Federal Law to Investigational Use Only and is not CE marked for commercialization.

CircuLite® and Synergy® are registered trademarks of CircuLite, Inc. in the United States.

Contacts

Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
or
CircuLite, Inc.:
Gail Farnan, 201-478-7651
Vice President, Marketing

Release Summary

Daniel Burkhoff, M.D., Ph.D., CircuLite's Chief Medical Officer, will present at the Lazard Capital Markets Healthcare Conference on November 16 at 9:00AM EST.

Contacts

Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
or
CircuLite, Inc.:
Gail Farnan, 201-478-7651
Vice President, Marketing